Page 120 - Human Use News Today

Investegate announcements from Formycon AG, Formycon announces EU-Approval of FYB201/Ranivisio®1 a biosimilar to Lucentis®2

COPENHAGEN, Denmark, August 24, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Teclistamab, an off-the-shelf (ready to use) subcutaneously administered therapy, induced deep and rapid responses in triple-class exposed patients with relapsed and refractory multiple myeloma1 The

PRESS RELEASE AB SCIENCE ANNOUNCES FILING OF MARKETING AUTHORIZATION APPLICATION FOR ALSITEK IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS...

Cuestion, to build such a huge rocket? great question. when — to build such a huge rocket? great question, when we _ to build such a huge rocket? great question, when we are _ to build such a huge rocket? great question, when we are going - to build such a huge rocket?

Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone Daiichi Sankyo (TSE: 4568) today announced

Press release content from Business Wire. The AP news staff was not involved in its creation.

Celltrion receives approval to sell anticancer biosimilar Vegzelma in Europe

European Commission approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the treatment of multiple types of cancer ·         Vegzelma™ offers European patients living with certain types of breast, lung, renal, colon, rect...